ArticleBMC veterinary research2026
vetInspECT: a platform for the multicentric evaluation of treatment response after electrochemotherapy in veterinary oncology - feline tumors.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Electrochemotherapy (ECT) is a local ablative treatment and in veterinary oncology, evidence supporting ECT efficacy is mainly derived from case reports and small case series, underscoring the need for standardized, multicentric data collection comparable to human oncology registries. The primary aim of this study was to establish VetInspECT, a veterinary clinical registry adapted from the human InspECT platform, to enable standardized reporting and multicentre data collection for ECT. The secondary aim was to evaluate antitumor effectiveness using data from the single centre that initiated the registry. VetInspECT was designed to systematically record patient characteristics, tumor features, treatment parameters, and follow-up outcomes in animals treated with ECT. Retrospective data spanning from 2012 to 2024 from feline patients treated at a Slovenian center were entered into the database. Squamous cell carcinoma (SCC) was the most frequently treated tumor (66%), followed by mast cell tumors (MCT; 12%) and other carcinomas and sarcomas. Complete response rates were highest in MCT (95%), followed by non-SCC carcinomas (90%), SCC (74%), and sarcomas (33%). Tumor size, clinical stage, anatomical location, and mucosal involvement significantly affected treatment response and progression-free survival. In conclusion, VetInspECT represents an important step toward standardized ECT reporting in veterinary oncology and supports the use of shared registries to enable robust multicentric analyses and broader clinical integration of ECT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.